A Long Road to May: What uniQure's Huntington's Gene Therapy Priority Review Actually Means

On November 2, 2026, uniQure announced that the FDA had accepted its biologics license application for ifezuntirgene inilparvovec, known as AMT-130, under priority review, with a PDUFA target action date of May 1, 2027. For a company that has spent the better part of a decade navigating one of the most turbulent regulatory relationships in recent biotech history, the acceptance is a milestone worth examining carefully. Not because it guarantees approval, but because of what the journey to this point reveals about how the FDA handles gene therapy in rare neurological disease, and what the data actually support.

The Drug and What It Does

AMT-130 is a one-time gene therapy delivered directly into the brain through small holes in the skull. It uses an adeno-associated virus vector to deliver a microRNA designed to silence the huntingtin gene, the source of the toxic protein that accumulates in the neurons of Huntington's disease patients and drives the progressive neurodegeneration that defines the illness. Huntington's is a fatal inherited disease with no approved disease-modifying treatment. Patients carry a genetic mutation that guarantees the disease will develop, typically in midlife, and progress relentlessly through motor, cognitive, and psychiatric deterioration until death. The unmet need is absolute.

The phase 1/2 trial that forms the basis of the FDA submission enrolled patients at two dose levels. At the 36-month analysis, published in September 2025, patients who received the higher dose showed a statistically significant 75% slowing of disease progression on the composite Unified Huntington's Disease Rating Scale. That result was compelling enough that uniQure sought accelerated approval on the strength of it. The FDA initially agreed, then reversed course, then reversed again. In June 2026, the agency gave uniQure the go-ahead to file based on the 36-month data. The company did so, and the FDA has now accepted that filing.

The Data Complication That Cannot Be Ignored

Here is where the story becomes genuinely complicated. In the months between the FDA's June green light and the November acceptance, uniQure reported the 48-month analysis from the same trial. The results were weaker. At 48 months, AMT-130 showed a 44% slowing of disease progression on the same scale, falling short of statistical significance. The stock fell 41% on the day of that disclosure. The company has been careful to note that the FDA submission was based on the 36-month analysis, not the 48-month data, and that the agency accepted the filing on that basis.

That distinction matters legally and regulatorily, but it creates an uncomfortable analytical situation. The FDA will review the 36-month data as the primary basis for its decision, but the 48-month data exist and will be part of the totality of evidence the agency considers. A therapy that showed 75% slowing at 36 months and 44% slowing at 48 months, with the latter missing statistical significance, is not a therapy whose efficacy trajectory is moving in the right direction. Whether the FDA interprets that pattern as a signal of waning effect, a statistical artifact of a small open-label trial, or something that the confirmatory study will resolve, is the central question the advisory committee meeting will need to address.

The Accelerated Approval Calculus

The FDA's willingness to accept the filing under accelerated approval reflects a judgment that the 36-month data represent a reasonable likelihood of clinical benefit in a disease with no alternatives. That is the statutory standard for accelerated approval, and it is a lower bar than full approval requires. The agency has agreed with uniQure on the key elements of a confirmatory trial: 200 patients randomized 2-to-1 to AMT-130 or standard of care, with total functional capacity as the primary endpoint at 35 months. Patient screening is expected to begin before the end of 2026, ensuring the study is underway before any approval decision is made.

The confirmatory trial design is important because it will need to resolve what the phase 1/2 data cannot. An open-label study in a small number of patients, without a randomized control arm, cannot definitively establish that the observed slowing of progression is caused by the drug rather than by natural variation in disease course, patient selection, or the placebo effect of intensive clinical monitoring. The 200-patient randomized study is designed to answer that question with the statistical power the phase 1/2 trial lacked.

What This Means for Huntington's Patients

For the approximately 30,000 Americans living with Huntington's disease, and the many more who carry the mutation and know what is coming, the priority review acceptance is meaningful news. It means the FDA has committed to a six-month review timeline and has signaled that the data are sufficient to warrant serious regulatory consideration. It does not mean approval is certain. The advisory committee meeting the FDA has tentatively planned will be a critical moment, and the agency's assessment of the 48-month data alongside the 36-month filing basis will shape the outcome.

What the uniQure story illustrates more broadly is the difficulty of developing gene therapies for progressive neurological diseases in small patient populations. The tools available to measure disease progression in Huntington's are imperfect. The natural history of the disease is variable. The trial sizes that are feasible in rare disease are rarely large enough to produce the statistical certainty that regulators and clinicians would prefer. The FDA's back-and-forth with uniQure over the past several years is not a story of regulatory dysfunction. It is a story of a genuinely hard scientific and evidentiary problem being worked through in real time, with a disease community watching every step.

If AMT-130 is approved in May 2027, it will be the first disease-modifying treatment for Huntington's disease in history. That would be a genuine milestone, not just for uniQure, but for the field of neurological gene therapy and for the patients who have been waiting for it. The road to that outcome is not clear. But for the first time in a long time, it is at least visible.